PolarityTE, Inc.
PolarityTE, Inc. (PTE) Stock Competitors & Peer Comparison
See (PTE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PTE | $0.24 | -0.82% | 1.8M | -0.42 | -$0.58 | N/A |
| VRTX | $385.65 | +2.67% | 94B | 26.74 | $13.71 | N/A |
| REGN | $555.13 | -0.83% | 58.6B | 14.18 | $39.69 | +0.31% |
| ALNY | $428.14 | -1.60% | 57.5B | -176.99 | -$2.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $673.15 | +0.12% | 40.5B | 33.72 | $19.63 | N/A |
| BNTX | $111.30 | -0.04% | 26.8B | -67.27 | -$1.66 | N/A |
| SMMT | $28.52 | +1.60% | 21.3B | -84.29 | -$0.34 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
PTE vs VRTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, VRTX has a market cap of 94B. Regarding current trading prices, PTE is priced at $0.24, while VRTX trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas VRTX's P/E ratio is 26.74. In terms of profitability, PTE's ROE is +0.57%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, PTE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check VRTX's competition here
PTE vs REGN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, REGN has a market cap of 58.6B. Regarding current trading prices, PTE is priced at $0.24, while REGN trades at $555.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas REGN's P/E ratio is 14.18. In terms of profitability, PTE's ROE is +0.57%, compared to REGN's ROE of +0.15%. Regarding short-term risk, PTE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check REGN's competition here
PTE vs ALNY Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ALNY has a market cap of 57.5B. Regarding current trading prices, PTE is priced at $0.24, while ALNY trades at $428.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ALNY's P/E ratio is -176.99. In terms of profitability, PTE's ROE is +0.57%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, PTE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ALNY's competition here
PTE vs SGEN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PTE is priced at $0.24, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PTE's ROE is +0.57%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PTE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check SGEN's competition here
PTE vs ARGX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ARGX has a market cap of 40.5B. Regarding current trading prices, PTE is priced at $0.24, while ARGX trades at $673.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ARGX's P/E ratio is 33.72. In terms of profitability, PTE's ROE is +0.57%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, PTE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ARGX's competition here
PTE vs BNTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BNTX has a market cap of 26.8B. Regarding current trading prices, PTE is priced at $0.24, while BNTX trades at $111.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BNTX's P/E ratio is -67.27. In terms of profitability, PTE's ROE is +0.57%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, PTE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BNTX's competition here
PTE vs SMMT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, SMMT has a market cap of 21.3B. Regarding current trading prices, PTE is priced at $0.24, while SMMT trades at $28.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas SMMT's P/E ratio is -84.29. In terms of profitability, PTE's ROE is +0.57%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, PTE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check SMMT's competition here
PTE vs BGNE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PTE is priced at $0.24, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PTE's ROE is +0.57%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, PTE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BGNE's competition here
PTE vs DNA-WT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PTE is priced at $0.24, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PTE's ROE is +0.57%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, PTE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check DNA-WT's competition here
PTE vs RPRX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RPRX has a market cap of 15.8B. Regarding current trading prices, PTE is priced at $0.24, while RPRX trades at $37.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RPRX's P/E ratio is 16.41. In terms of profitability, PTE's ROE is +0.57%, compared to RPRX's ROE of +0.14%. Regarding short-term risk, PTE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RPRX's competition here
PTE vs INCY Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, INCY has a market cap of 15.3B. Regarding current trading prices, PTE is priced at $0.24, while INCY trades at $77.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas INCY's P/E ratio is 18.53. In terms of profitability, PTE's ROE is +0.57%, compared to INCY's ROE of +0.34%. Regarding short-term risk, PTE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check INCY's competition here
PTE vs UTHR Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, UTHR has a market cap of 13.6B. Regarding current trading prices, PTE is priced at $0.24, while UTHR trades at $302.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas UTHR's P/E ratio is 11.87. In terms of profitability, PTE's ROE is +0.57%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PTE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check UTHR's competition here
PTE vs GMAB Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, GMAB has a market cap of 13.2B. Regarding current trading prices, PTE is priced at $0.24, while GMAB trades at $21.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas GMAB's P/E ratio is 12.61. In terms of profitability, PTE's ROE is +0.57%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, PTE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check GMAB's competition here
PTE vs KRTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PTE is priced at $0.24, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PTE's ROE is +0.57%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PTE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check KRTX's competition here
PTE vs ASND Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ASND has a market cap of 11.6B. Regarding current trading prices, PTE is priced at $0.24, while ASND trades at $182.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ASND's P/E ratio is -28.50. In terms of profitability, PTE's ROE is +0.57%, compared to ASND's ROE of +1.91%. Regarding short-term risk, PTE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ASND's competition here
PTE vs BMRN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, PTE is priced at $0.24, while BMRN trades at $60.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BMRN's P/E ratio is 17.27. In terms of profitability, PTE's ROE is +0.57%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, PTE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BMRN's competition here
PTE vs MRNA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MRNA has a market cap of 10.2B. Regarding current trading prices, PTE is priced at $0.24, while MRNA trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MRNA's P/E ratio is -3.48. In terms of profitability, PTE's ROE is +0.57%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, PTE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MRNA's competition here
PTE vs EXEL Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, PTE is priced at $0.24, while EXEL trades at $37.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas EXEL's P/E ratio is 18.13. In terms of profitability, PTE's ROE is +0.57%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, PTE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check EXEL's competition here
PTE vs RXDX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PTE is priced at $0.24, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PTE's ROE is +0.57%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PTE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RXDX's competition here
PTE vs VRNA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, PTE is priced at $0.24, while VRNA trades at $105.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas VRNA's P/E ratio is -101.23. In terms of profitability, PTE's ROE is +0.57%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, PTE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check VRNA's competition here
PTE vs BBIO Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BBIO has a market cap of 8.9B. Regarding current trading prices, PTE is priced at $0.24, while BBIO trades at $44.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BBIO's P/E ratio is -11.28. In terms of profitability, PTE's ROE is +0.57%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, PTE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BBIO's competition here
PTE vs IMGN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PTE is priced at $0.24, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PTE's ROE is +0.57%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, PTE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check IMGN's competition here
PTE vs BPMC Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PTE is priced at $0.24, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PTE's ROE is +0.57%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, PTE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BPMC's competition here
PTE vs CERE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PTE is priced at $0.24, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CERE's P/E ratio is -16.47. In terms of profitability, PTE's ROE is +0.57%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PTE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CERE's competition here
PTE vs TECH Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, PTE is priced at $0.24, while TECH trades at $49.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas TECH's P/E ratio is 109.61. In terms of profitability, PTE's ROE is +0.57%, compared to TECH's ROE of +0.06%. Regarding short-term risk, PTE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for PTE.Check TECH's competition here
PTE vs ROIVW Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, PTE is priced at $0.24, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, PTE's ROE is +0.57%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, PTE is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ROIVW's competition here
PTE vs ROIV Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, PTE is priced at $0.24, while ROIV trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ROIV's P/E ratio is -15.32. In terms of profitability, PTE's ROE is +0.57%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, PTE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ROIV's competition here
PTE vs MDGL Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MDGL has a market cap of 7.7B. Regarding current trading prices, PTE is priced at $0.24, while MDGL trades at $338.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MDGL's P/E ratio is -27.33. In terms of profitability, PTE's ROE is +0.57%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, PTE is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MDGL's competition here
PTE vs CORT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, PTE is priced at $0.24, while CORT trades at $70.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CORT's P/E ratio is 64.55. In terms of profitability, PTE's ROE is +0.57%, compared to CORT's ROE of +0.20%. Regarding short-term risk, PTE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CORT's competition here
PTE vs HALO Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, PTE is priced at $0.24, while HALO trades at $62.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas HALO's P/E ratio is 14.46. In terms of profitability, PTE's ROE is +0.57%, compared to HALO's ROE of +1.37%. Regarding short-term risk, PTE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check HALO's competition here
PTE vs JAZZ Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, PTE is priced at $0.24, while JAZZ trades at $105.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas JAZZ's P/E ratio is -15.95. In terms of profitability, PTE's ROE is +0.57%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, PTE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check JAZZ's competition here
PTE vs IONS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, PTE is priced at $0.24, while IONS trades at $40.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas IONS's P/E ratio is -23.39. In terms of profitability, PTE's ROE is +0.57%, compared to IONS's ROE of -0.45%. Regarding short-term risk, PTE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check IONS's competition here
PTE vs RETA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PTE is priced at $0.24, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RETA's P/E ratio is -66.29. In terms of profitability, PTE's ROE is +0.57%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PTE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RETA's competition here
PTE vs RVMD Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RVMD has a market cap of 6.5B. Regarding current trading prices, PTE is priced at $0.24, while RVMD trades at $36.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RVMD's P/E ratio is -7.74. In terms of profitability, PTE's ROE is +0.57%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, PTE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RVMD's competition here
PTE vs RYTM Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, PTE is priced at $0.24, while RYTM trades at $90.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RYTM's P/E ratio is -30.56. In terms of profitability, PTE's ROE is +0.57%, compared to RYTM's ROE of -2.26%. Regarding short-term risk, PTE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RYTM's competition here
PTE vs RNA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RNA has a market cap of 5.6B. Regarding current trading prices, PTE is priced at $0.24, while RNA trades at $48.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RNA's P/E ratio is -15.43. In terms of profitability, PTE's ROE is +0.57%, compared to RNA's ROE of -0.27%. Regarding short-term risk, PTE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for PTE.Check RNA's competition here
PTE vs ABCM Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PTE is priced at $0.24, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PTE's ROE is +0.57%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PTE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ABCM's competition here
PTE vs ISEE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PTE is priced at $0.24, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PTE's ROE is +0.57%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PTE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ISEE's competition here
PTE vs NUVL Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, PTE is priced at $0.24, while NUVL trades at $77.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas NUVL's P/E ratio is -15.06. In terms of profitability, PTE's ROE is +0.57%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, PTE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check NUVL's competition here
PTE vs ABVX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, PTE is priced at $0.24, while ABVX trades at $69.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ABVX's P/E ratio is -20.51. In terms of profitability, PTE's ROE is +0.57%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, PTE is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ABVX's competition here
PTE vs AXSM Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, PTE is priced at $0.24, while AXSM trades at $103.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas AXSM's P/E ratio is -20.51. In terms of profitability, PTE's ROE is +0.57%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, PTE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check AXSM's competition here
PTE vs CRSP Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, PTE is priced at $0.24, while CRSP trades at $56.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CRSP's P/E ratio is -10.26. In terms of profitability, PTE's ROE is +0.57%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, PTE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CRSP's competition here
PTE vs MRUS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MRUS has a market cap of 4.8B. Regarding current trading prices, PTE is priced at $0.24, while MRUS trades at $65.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MRUS's P/E ratio is -11.47. In terms of profitability, PTE's ROE is +0.57%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, PTE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MRUS's competition here
PTE vs ALPN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PTE is priced at $0.24, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PTE's ROE is +0.57%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PTE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ALPN's competition here
PTE vs ALKS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, PTE is priced at $0.24, while ALKS trades at $26.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ALKS's P/E ratio is 12.90. In terms of profitability, PTE's ROE is +0.57%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, PTE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ALKS's competition here
PTE vs SLNO Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, PTE is priced at $0.24, while SLNO trades at $81.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas SLNO's P/E ratio is -19.51. In terms of profitability, PTE's ROE is +0.57%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, PTE is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check SLNO's competition here
PTE vs VKTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, PTE is priced at $0.24, while VKTX trades at $31.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas VKTX's P/E ratio is -24.60. In terms of profitability, PTE's ROE is +0.57%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, PTE is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check VKTX's competition here
PTE vs TGTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, TGTX has a market cap of 4.2B. Regarding current trading prices, PTE is priced at $0.24, while TGTX trades at $27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas TGTX's P/E ratio is 70.29. In terms of profitability, PTE's ROE is +0.57%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, PTE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check TGTX's competition here
PTE vs OPT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PTE is priced at $0.24, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas OPT's P/E ratio is -1.52. In terms of profitability, PTE's ROE is +0.57%, compared to OPT's ROE of +2.60%. Regarding short-term risk, PTE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check OPT's competition here
PTE vs MRTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PTE is priced at $0.24, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PTE's ROE is +0.57%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PTE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MRTX's competition here
PTE vs ACAD Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ACAD has a market cap of 4.1B. Regarding current trading prices, PTE is priced at $0.24, while ACAD trades at $23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ACAD's P/E ratio is 18.50. In terms of profitability, PTE's ROE is +0.57%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, PTE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ACAD's competition here
PTE vs CYTK Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, PTE is priced at $0.24, while CYTK trades at $35.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CYTK's P/E ratio is -6.45. In terms of profitability, PTE's ROE is +0.57%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, PTE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CYTK's competition here
PTE vs AKRO Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, PTE is priced at $0.24, while AKRO trades at $52.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas AKRO's P/E ratio is -13.46. In terms of profitability, PTE's ROE is +0.57%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, PTE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check AKRO's competition here
PTE vs KRYS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, PTE is priced at $0.24, while KRYS trades at $136.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas KRYS's P/E ratio is 28.24. In terms of profitability, PTE's ROE is +0.57%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, PTE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check KRYS's competition here
PTE vs ADMA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ADMA has a market cap of 3.9B. Regarding current trading prices, PTE is priced at $0.24, while ADMA trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ADMA's P/E ratio is 19.44. In terms of profitability, PTE's ROE is +0.57%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, PTE is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ADMA's competition here
PTE vs ACLX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, PTE is priced at $0.24, while ACLX trades at $70.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ACLX's P/E ratio is -23.58. In terms of profitability, PTE's ROE is +0.57%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, PTE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ACLX's competition here
PTE vs PCVX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, PCVX has a market cap of 3.9B. Regarding current trading prices, PTE is priced at $0.24, while PCVX trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas PCVX's P/E ratio is -7.27. In terms of profitability, PTE's ROE is +0.57%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, PTE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check PCVX's competition here
PTE vs AAPG Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, AAPG has a market cap of 3.9B. Regarding current trading prices, PTE is priced at $0.24, while AAPG trades at $42.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas AAPG's P/E ratio is -56.62. In terms of profitability, PTE's ROE is +0.57%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, PTE is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check AAPG's competition here
PTE vs ZLAB Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, PTE is priced at $0.24, while ZLAB trades at $38.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ZLAB's P/E ratio is -17.48. In terms of profitability, PTE's ROE is +0.57%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, PTE is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ZLAB's competition here
PTE vs TLX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, PTE is priced at $0.24, while TLX trades at $11.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas TLX's P/E ratio is 126.00. In terms of profitability, PTE's ROE is +0.57%, compared to TLX's ROE of +0.06%. Regarding short-term risk, PTE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check TLX's competition here
PTE vs RYZB Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PTE is priced at $0.24, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PTE's ROE is +0.57%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PTE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RYZB's competition here
PTE vs CBAY Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PTE is priced at $0.24, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PTE's ROE is +0.57%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PTE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CBAY's competition here
PTE vs PTCT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, PTCT has a market cap of 3.6B. Regarding current trading prices, PTE is priced at $0.24, while PTCT trades at $51.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas PTCT's P/E ratio is 6.97. In terms of profitability, PTE's ROE is +0.57%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, PTE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check PTCT's competition here
PTE vs SWTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PTE is priced at $0.24, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PTE's ROE is +0.57%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, PTE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check SWTX's competition here
PTE vs LEGN Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, PTE is priced at $0.24, while LEGN trades at $37.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas LEGN's P/E ratio is -31.36. In terms of profitability, PTE's ROE is +0.57%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, PTE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check LEGN's competition here
PTE vs MLTX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MLTX has a market cap of 3.3B. Regarding current trading prices, PTE is priced at $0.24, while MLTX trades at $52.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MLTX's P/E ratio is -18.78. In terms of profitability, PTE's ROE is +0.57%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, PTE is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MLTX's competition here
PTE vs MTSR Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, PTE is priced at $0.24, while MTSR trades at $33.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MTSR's P/E ratio is -10.34. In terms of profitability, PTE's ROE is +0.57%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, PTE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MTSR's competition here
PTE vs PTGX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, PTGX has a market cap of 3.2B. Regarding current trading prices, PTE is priced at $0.24, while PTGX trades at $53.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas PTGX's P/E ratio is 69.96. In terms of profitability, PTE's ROE is +0.57%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, PTE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check PTGX's competition here
PTE vs APLS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, PTE is priced at $0.24, while APLS trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas APLS's P/E ratio is -13.32. In terms of profitability, PTE's ROE is +0.57%, compared to APLS's ROE of -1.16%. Regarding short-term risk, PTE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check APLS's competition here
PTE vs SRRK Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, PTE is priced at $0.24, while SRRK trades at $34.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas SRRK's P/E ratio is -10.94. In terms of profitability, PTE's ROE is +0.57%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, PTE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for PTE.Check SRRK's competition here
PTE vs NAMSW Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, PTE is priced at $0.24, while NAMSW trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas NAMSW's P/E ratio is N/A. In terms of profitability, PTE's ROE is +0.57%, compared to NAMSW's ROE of -0.22%. Regarding short-term risk, PTE is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check NAMSW's competition here
PTE vs MIRM Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MIRM has a market cap of 3B. Regarding current trading prices, PTE is priced at $0.24, while MIRM trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MIRM's P/E ratio is -33.13. In terms of profitability, PTE's ROE is +0.57%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, PTE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MIRM's competition here
PTE vs LGND Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, LGND has a market cap of 2.9B. Regarding current trading prices, PTE is priced at $0.24, while LGND trades at $142.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas LGND's P/E ratio is -20.58. In terms of profitability, PTE's ROE is +0.57%, compared to LGND's ROE of -0.09%. Regarding short-term risk, PTE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check LGND's competition here
PTE vs MORF Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, PTE is priced at $0.24, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MORF's P/E ratio is -14.88. In terms of profitability, PTE's ROE is +0.57%, compared to MORF's ROE of -0.22%. Regarding short-term risk, PTE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MORF's competition here
PTE vs MOR Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, PTE is priced at $0.24, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MOR's P/E ratio is -12.64. In terms of profitability, PTE's ROE is +0.57%, compared to MOR's ROE of -1.84%. Regarding short-term risk, PTE is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MOR's competition here
PTE vs NAMS Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, NAMS has a market cap of 2.9B. Regarding current trading prices, PTE is priced at $0.24, while NAMS trades at $23.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas NAMS's P/E ratio is -15.92. In terms of profitability, PTE's ROE is +0.57%, compared to NAMS's ROE of -0.22%. Regarding short-term risk, PTE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for PTE.Check NAMS's competition here
PTE vs KYMR Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, PTE is priced at $0.24, while KYMR trades at $41.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas KYMR's P/E ratio is -13.06. In terms of profitability, PTE's ROE is +0.57%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, PTE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check KYMR's competition here
PTE vs KDNY Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, PTE is priced at $0.24, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas KDNY's P/E ratio is -12.47. In terms of profitability, PTE's ROE is +0.57%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, PTE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check KDNY's competition here
PTE vs IMVT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, PTE is priced at $0.24, while IMVT trades at $15.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas IMVT's P/E ratio is -5.66. In terms of profitability, PTE's ROE is +0.57%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, PTE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check IMVT's competition here
PTE vs MYOV Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, PTE is priced at $0.24, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas MYOV's P/E ratio is -14.05. In terms of profitability, PTE's ROE is +0.57%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, PTE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check MYOV's competition here
PTE vs RARE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, PTE is priced at $0.24, while RARE trades at $28.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RARE's P/E ratio is -5.03. In terms of profitability, PTE's ROE is +0.57%, compared to RARE's ROE of -2.37%. Regarding short-term risk, PTE is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RARE's competition here
PTE vs XENE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, PTE is priced at $0.24, while XENE trades at $34.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas XENE's P/E ratio is -10.38. In terms of profitability, PTE's ROE is +0.57%, compared to XENE's ROE of -0.32%. Regarding short-term risk, PTE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check XENE's competition here
PTE vs CRNX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CRNX has a market cap of 2.5B. Regarding current trading prices, PTE is priced at $0.24, while CRNX trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CRNX's P/E ratio is -7.07. In terms of profitability, PTE's ROE is +0.57%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, PTE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CRNX's competition here
PTE vs CPRX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CPRX has a market cap of 2.4B. Regarding current trading prices, PTE is priced at $0.24, while CPRX trades at $21.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CPRX's P/E ratio is 12.04. In terms of profitability, PTE's ROE is +0.57%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, PTE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CPRX's competition here
PTE vs KNSA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, PTE is priced at $0.24, while KNSA trades at $32.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas KNSA's P/E ratio is 643.00. In terms of profitability, PTE's ROE is +0.57%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, PTE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check KNSA's competition here
PTE vs PRVB Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, PTE is priced at $0.24, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas PRVB's P/E ratio is -16.43. In terms of profitability, PTE's ROE is +0.57%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, PTE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check PRVB's competition here
PTE vs LBPH Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas LBPH's P/E ratio is -26.66. In terms of profitability, PTE's ROE is +0.57%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, PTE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check LBPH's competition here
PTE vs IBRX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while IBRX trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas IBRX's P/E ratio is -5.08. In terms of profitability, PTE's ROE is +0.57%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, PTE is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check IBRX's competition here
PTE vs RXRX Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while RXRX trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas RXRX's P/E ratio is -2.96. In terms of profitability, PTE's ROE is +0.57%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, PTE is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check RXRX's competition here
PTE vs BLTE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while BLTE trades at $67.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas BLTE's P/E ratio is -51.38. In terms of profitability, PTE's ROE is +0.57%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, PTE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check BLTE's competition here
PTE vs CNTA Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while CNTA trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CNTA's P/E ratio is -9.05. In terms of profitability, PTE's ROE is +0.57%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, PTE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CNTA's competition here
PTE vs DICE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas DICE's P/E ratio is -21.91. In terms of profitability, PTE's ROE is +0.57%, compared to DICE's ROE of +0.56%. Regarding short-term risk, PTE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check DICE's competition here
PTE vs ARWR Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, PTE is priced at $0.24, while ARWR trades at $16.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas ARWR's P/E ratio is -13.24. In terms of profitability, PTE's ROE is +0.57%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, PTE is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check ARWR's competition here
PTE vs CALT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas CALT's P/E ratio is -22.73. In terms of profitability, PTE's ROE is +0.57%, compared to CALT's ROE of -1.67%. Regarding short-term risk, PTE is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check CALT's competition here
PTE vs GLPG Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, GLPG has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while GLPG trades at $32.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas GLPG's P/E ratio is -6.42. In terms of profitability, PTE's ROE is +0.57%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, PTE is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check GLPG's competition here
PTE vs VCYT Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while VCYT trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas VCYT's P/E ratio is 80.50. In terms of profitability, PTE's ROE is +0.57%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, PTE is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check VCYT's competition here
PTE vs OCUL Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, OCUL has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while OCUL trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas OCUL's P/E ratio is -9.69. In terms of profitability, PTE's ROE is +0.57%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, PTE is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check OCUL's competition here
PTE vs APGE Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, APGE has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while APGE trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas APGE's P/E ratio is -9.80. In terms of profitability, PTE's ROE is +0.57%, compared to APGE's ROE of -0.19%. Regarding short-term risk, PTE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check APGE's competition here
PTE vs FOLD Comparison August 2025
PTE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PTE stands at 1.8M. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, PTE is priced at $0.24, while FOLD trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PTE currently has a P/E ratio of -0.42, whereas FOLD's P/E ratio is -56.33. In terms of profitability, PTE's ROE is +0.57%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, PTE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for PTE.Check FOLD's competition here